drugset / Trial / NCT04625153
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the dose-response relationship and provide a dose basis for follow-up clinical trials.
Timeline
- Start
- 2021-05-13
- Primary completion
- 2026-04-03
- Completion
- 2026-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |